Epigenetic Reprogramming as a Therapeutic Strategy for Aging and Degenerative Diseases

<p><span>Aging is the primary risk factor for numerous degenerative diseases, including neurodegenerative disorders, cardiovascular diseases, and metabolic dysfunction. Emerging research suggests that aging is not solely a consequence of irreversible molecular damage but is also driven by reversible epigenetic alterations that accumulate over time. Epigenetic reprogramming the process of resetting cellular epigenetic states has recently gained attention as a potential therapeutic strategy capable of reversing biological aging and restoring cellular function. Advances in cellular reprogramming technologies, particularly those involving the transcription factors Oct4, Sox2, Klf4, and c-Myc (collectively known as Yamanaka factors), have demonstrated the possibility of rejuvenating aged cells and tissues by resetting epigenetic marks. Studies show that partial cellular reprogramming can reverse epigenetic aging signatures, enhance tissue regeneration, and improve functional outcomes in experimental models. Shinya Yamanaka's discovery of induced pluripotent stem cells has thus transformed the scientific understanding of aging plasticity. Despite promising findings, challenges remain, including tumorigenicity, loss of cellular identity, and ethical considerations associated with gene manipulation. This paper examines the molecular mechanisms underlying epigenetic aging, reviews current approaches to epigenetic reprogramming, and evaluates its therapeutic potential for treating age-related degenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and muscular degeneration. The study concludes that epigenetic reprogramming represents a transformative frontier in regenerative medicine but requires careful translational research to ensure safety, efficacy, and ethical implementation.</span></p>